TL;DR:
- Ozette Technologies, Inc. introduces the Assay-to-Insights product, revolutionizing immune system exploration in fresh and frozen samples.
- The product combines Ozette’s three proprietary technologies: Ozette Laboratory, Ozette Endpoints™, and Ozette Discovery™.
- Ozette Endpoints™ offers rapid access to decision-enabling data for clinical biomarker teams, surpassing legacy solutions in speed and quality.
- Ozette Discovery™ provides unbiased automated cell population discovery and annotation from single-cell cytometry data, saving time for lab and bioinformatics scientists.
- The Ozette Platform™ enables clinical teams to interact and explore cytometry data through a cloud-based system.
- Ozette launches the Assay-to-Insights Partner Grant Program, encouraging eligible researchers to apply via their website.
- The technology developed by Ozette supports the entire therapy development cycle, from preclinical research to FDA approval.
- Ozette’s advancements in single-cell cytometry data analysis contribute to a better understanding of immunology and disease.
- Collaboration, transparency, and rapid access to insights are key focus areas for Ozette.
- Their ultimate goal is to provide faster access to life-saving therapies for patients.
Main AI News:
Ozette Technologies, Inc., a visionary life sciences company driven by technology, has unveiled its groundbreaking Assay-to-Insights product. This cutting-edge solution offers a streamlined and state-of-the-art process for exploring the immune system in both fresh and frozen samples. By harnessing the power of three proprietary technologies developed by Ozette, this innovative product sets a new standard in the field.
The first of these technologies is Ozette Laboratory, a facility operating under the strict guidelines of Good Clinical Laboratory Practices (GCLP). This world-class data generation hub ensures the highest quality standards in data collection. Next is Ozette Endpoints™, a tool that enables rapid computational monitoring of pre-defined biomarker endpoints. This revolutionary feature allows for quick and accurate identification of target or novel cell phenotypes, surpassing the capabilities of traditional methods.
The third technology, Ozette Discovery™, brings forth an era of unbiased discovery and annotation of single-cell cytometry data. This breakthrough automated system provides robust and transparent analysis, revolutionizing the workflow for lab scientists and bioinformatics experts. With Ozette Discovery™, researchers can explore their single-cell data in real-time and in context, enabling comprehensive insights and saving valuable time.
To facilitate the dissemination of these insights, Ozette offers the Ozette Platform™, a cloud-based system that serves as a central dashboard for clinical teams. This platform provides access to the invaluable data generated by Ozette Endpoints™ and Ozette Discovery™, empowering researchers to interact and explore cytometry data seamlessly.
In conjunction with the launch of Assay-to-Insights, Ozette is proud to announce the Assay-to-Insights Partner Grant Program. This program invites researchers who meet Ozette’s eligibility requirements to apply and make inquiries through the company’s official website. By fostering collaboration and innovation, Ozette aims to further advance the field of life sciences.
Cherie Green, Vice President of Translational Science at Ozette, affirms the transformative impact of Ozette Endpoints™, stating, “Our clinical investigators now possess robust tools that deliver key biomarker endpoints with unparalleled speed and resolution, all within an integrated platform.” With the support of Ozette’s in-house experts in clinical biomarkers and a purpose-built computational analysis platform, clinical trial teams gain access to rapid, reproducible, and transparent results. This enables informed decision-making, driving faster progress in clinical trials and ultimately improving patient outcomes.
Ozette Discovery™, on the other hand, revolutionizes the way scientists approach single-cell cytometry data analysis. This best-in-class technology allows researchers, from immunologists to computational biologists, to explore and annotate cell populations with unbiased precision.
By providing a transformative computational environment through the Ozette platform, scientists can collaborate seamlessly and access longitudinal data observed in clinical trials. This standardized and transparent analysis of diverse single-cell proteomic technologies empowers researchers to uncover meaningful insights efficiently.
Ali Ansary, CEO and Co-Founder of Ozette emphasizes the broader impact of their technology, saying, “We have developed a technology that supports the entire therapy development cycle, from preclinical research to FDA approval.” With Ozette’s groundbreaking advancements in decoding clinically relevant insights from single-cell cytometry data, they contribute to the world’s understanding of immunology and disease. This invaluable knowledge accelerates the availability of life-saving therapies, ensuring patients can access them more rapidly.
Conlcusion:
The introduction of Ozette Technologies’ Assay-to-Insights product signifies a significant advancement in the market for immune system exploration and analysis. By combining cutting-edge technologies, such as Ozette Laboratory, Ozette Endpoints™, and Ozette Discovery™, with the cloud-based Ozette Platform™, Ozette Technologies has created a comprehensive solution that enhances speed, accuracy, transparency, and collaboration in the field of life sciences.
This breakthrough offers not only streamlines the clinical trial process but also empowers researchers to uncover meaningful insights from single-cell cytometry data more efficiently. With its focus on delivering faster access to life-saving therapies, Ozette Technologies is poised to make a profound impact on the market, transforming the future of clinical trials and ultimately improving patient outcomes.
